| BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk |
NCT01704378: Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes |
|
|
| Completed | 4 | 89 | Europe | biphasic insulin aspart | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 03/03 | 03/03 | | |
NCT01697631: Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes |
|
|
| Completed | 4 | 131 | Europe | biphasic insulin aspart 30, insulin aspart | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 04/03 | 04/03 | | |
NCT01467401: Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes |
|
|
| Completed | 4 | 292 | Europe | biphasic insulin aspart, biphasic human insulin | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 05/03 | 05/03 | | |
REACH , NCT01487798: Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes |
|
|
| Completed | 4 | 170 | Europe | biphasic human insulin 30, biphasic insulin aspart 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 11/03 | 11/03 | | |
NCT00605111: Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes |
|
|
| Completed | 4 | 193 | RoW | biphasic insulin aspart | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 10/04 | 10/04 | | |
NCT00791895: Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs |
|
|
| Completed | 4 | 102 | US | biphasic insulin aspart 30, BIASP, NovoLog® Mix 70/30, NovoMix® | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 10/04 | 11/04 | | |
NCT00592969: Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes |
|
|
| Completed | 4 | 164 | RoW | metformin, biphasic insulin aspart | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 11/04 | 11/04 | | |
NCT00600366: Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes |
|
|
| Completed | 4 | 71 | RoW | biphasic insulin aspart, BIASP, NovoMix 30, NovoLog 70/30 Mix | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 01/05 | 01/05 | | |
EUROMIX, NCT00619697: Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes |
|
|
| Completed | 4 | 260 | Europe | biphasic insulin aspart, BIASP, NovoMix 30, NovoLog 70/30 Mix, insulin glargine, metformin, glimepiride | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 03/05 | 03/05 | | |
NCT00624364: Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes |
|
|
| Completed | 4 | 140 | RoW | biphasic insulin aspart, metformin | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 05/05 | 05/05 | | |
NCT00184626: Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes. |
|
|
| Completed | 4 | 97 | RoW | biphasic insulin aspart, insulin glargine, metformin | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 10/05 | 10/05 | | |
NCT01486862: Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs |
|
|
| Completed | 4 | 26 | RoW | biphasic insulin aspart 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 07/06 | 07/06 | | |
NCT00282451: Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes |
|
|
| Completed | 4 | 79 | RoW | biphasic insulin aspart, insulin aspart | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 08/06 | 08/06 | | |
NCT00469092 / 2006-003288-29: Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes |
|
|
| Completed | 4 | 480 | Europe, RoW | biphasic insulin aspart, insulin glargine, metformin, glimepiride | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 04/08 | 04/08 | | |
IMPROVE, NCT00537277: Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs |
|
|
| Completed | 4 | 161 | RoW | biphasic insulin aspart, BIasp, NovoLog Mix 70/30, NovoMix 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 01/09 | 01/09 | | |
S019, NCT00393705 / 2006-003076-35: Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 |
|
|
| Completed | 4 | 302 | Europe, RoW | Insulin Biphasic Aspart 30/70, insulin lispro LM, Low Mix, Humalog, insulin lispro MM, Mid Mix | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 03/09 | 03/09 | | |
NCT00669864: Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin |
|
|
| Completed | 4 | 293 | RoW | biphasic insulin aspart 30, NovoMix® 30, metformin | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 04/09 | 04/09 | | |
NCT00807092: Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes |
|
|
| Completed | 4 | 145 | RoW | biphasic insulin aspart 30, biphasic human insulin 30, metformin | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 10/09 | 10/09 | | |
EasyMix, NCT01123980: Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment |
|
|
| Completed | 4 | 521 | Japan, RoW | biphasic insulin aspart 30, metformin, glimepiride, insulin glargine | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 06/11 | 06/11 | | |
|
NCT01278160: Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756 |
|
|
| Completed | 4 | 179 | RoW | biphasic insulin aspart 30, metformin | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 09/11 | 09/11 | | |
B to B, NCT01212913: Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) |
|
|
| Completed | 4 | 161 | RoW | INSULIN GLARGINE, Lantus, INSULIN GLULISINE, Apidra, Insulin aspart, NovoMix 30 | Sanofi | Diabetes Mellitus, Type 2 | 05/12 | 05/12 | | |
| Terminated | 4 | 52 | Europe | Insulin glulisine, Apidra®, Insulin glargine, Lantus®, Premixed insulin (Insulin Aspart 30/70 ), NovoMix 30/70® | Sanofi | Diabetes Mellitus, Type 2 | 07/12 | 07/12 | | |
SimpleMix, NCT01427920 / 2010-024303-27: Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes |
|
|
| Completed | 4 | 348 | Europe, RoW | biphasic insulin aspart 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 07/12 | 07/12 | | |
NCT01215435: Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone |
|
|
| Completed | 4 | 245 | RoW | biphasic insulin aspart 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 09/12 | 09/12 | | |
NCT01618214: Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes |
|
|
| Completed | 4 | 344 | RoW | biphasic insulin aspart 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 01/13 | 01/13 | | |
| Completed | 4 | 582 | Europe, RoW | biphasic insulin aspart 30, sitagliptin, metformin | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 10/13 | 10/13 | | |
NCT01589653: Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients |
|
|
| Completed | 4 | 155 | RoW | biphasic insulin aspart 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 07/15 | 07/15 | | |
NCT02453685 / 2014-003708-62: A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients |
|
|
| Completed | 4 | 335 | Europe, RoW | biphasic insulin aspart 30, insulin glargine, insulin aspart | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 09/16 | 09/16 | | |
